Welcome to our dedicated page for Athira Pharma news (Ticker: ATHA), a resource for investors and traders seeking the latest updates and insights on Athira Pharma stock.
Athira Pharma, Inc. (NASDAQ: ATHA), which has announced a transition to the name LeonaBio, Inc. with a new ticker "LONA," regularly issues news updates as a clinical-stage biopharmaceutical company headquartered in the Seattle, Washington area. Its press releases focus on the development of novel small molecule therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS).
News for ATHA commonly covers progress in the company’s lead programs, lasofoxifene and ATH-1105. Updates include clinical trial milestones such as completion of a first-in-human Phase 1 trial of ATH-1105 in healthy volunteers, presentations of safety, tolerability and pharmacokinetic data, and enrollment status for the Phase 3 ELAINE-3 trial of lasofoxifene in ER+, HER2-negative, ESR1-mutated metastatic breast cancer. The company also reports on preclinical findings for ATH-1105 in ALS models and scientific presentations at major neurology and ALS-focused conferences.
Investors following ATHA news will also see corporate and regulatory developments, including announcements about a 10-for-1 reverse stock split aimed at maintaining Nasdaq listing requirements, notices of regained compliance with the minimum bid price rule, and details of private placement financings intended to support clinical and regulatory milestones. Additional releases describe Athira’s strategic alternatives review and its licensing agreements with Sermonix Pharmaceuticals and Ligand Pharmaceuticals for lasofoxifene.
This news feed provides a centralized view of Athira/LeonaBio’s clinical, scientific and corporate disclosures, allowing readers to track how its oncology and neurology pipelines evolve over time and how financing and licensing arrangements relate to ongoing and planned trials.
Athira Pharma (NASDAQ: ATHA) announced an extension of its open-label treatment duration for the Phase 3 LIFT-AD and Phase 2 ACT-AD studies of fosgonimeton, increasing from 6 to 18 months. This decision follows a review by the independent Data and Safety Monitoring Board (DSMB). Participants who completed the initial trials can opt for continued treatment, reflecting strong interest from both investigators and patients. The LIFT-AD trial's topline results are expected in H1 2023, while ACT-AD results are targeted for Q2 2022.
Athira Pharma, Inc. (NASDAQ: ATHA) encourages shareholders to vote 'FOR' its independent director nominees—Joseph Edelman, John M. Fluke, Jr., and Grant Pickering—using the WHITE proxy card ahead of the annual meeting on May 19, 2022. The company highlights its progress in clinical trials, particularly for its lead candidate, fosgonimeton (ATH-1017), with topline results expected from the Phase 2 ACT-AD study by Q2 2022, and full enrollment of the LIFT-AD Phase 3 study targeted for Q3 2022. The board expresses confidence in its leadership amidst a proxy contest led by Richard Kayne, urging shareholders to support its current board to maintain momentum.
Richard A. Kayne, owning 4.8% of Athira Pharma, urges the Board to seek a new CEO with clinical experience to enhance the success rate of ongoing trials for ATH-1017. He proposed Dr. Ronald Krall, a former Chief Medical Officer at GlaxoSmithKline, citing his extensive experience overseeing 20 FDA approvals. Dr. Krall expresses readiness to lead Athira and improve the management of critical ACT-AD and LIFT-AD trials, emphasizing the need for experienced oversight in this pivotal phase for the company’s drug candidate.
Ric Kayne, a significant shareholder of Athira Pharma (NASDAQ: ATHA), has criticized the current Board of Directors for poor decision-making that has led to substantial shareholder value destruction. Highlighting recent missteps, including the termination of former CEO Dr. Leen Kawas and the promotion of inexperienced Dr. Mark Litton, Kayne calls for immediate changes to restore Board credibility. He emphasizes the urgency to elect new directors, including himself and George Bickerstaff, to safeguard the company’s future and enhance its Alzheimer’s treatment, ATH-1017.
Athira Pharma (NASDAQ: ATHA) is urging shareholders to vote for its independent director nominees ahead of its Annual Meeting. The company highlights its strategic position as it prepares for pivotal clinical data, including topline results from the Phase 2 ACT-AD study by Q2 2022 and full enrollment of the LIFT-AD Phase 3 study by Q3 2022. Athira emphasizes strong management with extensive biopharma experience and a robust board aimed at advancing its drug development strategies for neurodegenerative conditions. A proxy contest led by Richard Kayne is described as unnecessary and misaligned with shareholder interests.
Ric Kayne, who owns approximately 4.8% of Athira's common stock, has launched a campaign urging shareholders to vote for new directors to enhance oversight of clinical trials for ATH-1017. He criticizes the current Board for poor decision-making and governance failures, claiming it jeopardizes shareholder value and ATH-1017's potential. Kayne emphasizes the need for a capable Board with industry expertise to navigate ongoing clinical trials. He encourages shareholders to vote their BLUE proxy cards to ensure critical changes are made for long-term success.
Athira Pharma, Inc. (NASDAQ: ATHA) emphasizes the importance of shareholder support for its independent director nominees, Joseph Edelman, John M. Fluke, Jr., and Grant Pickering, urging votes on the WHITE proxy card. The company highlights recent additions to its board, consisting of seven new members within three years, who bring valuable skills across clinical development, regulatory processes, and finance. Athira aims to advance its clinical trials, particularly for fosgonimeton, amidst a proxy contest that threatens to disrupt its progress. It calls for shareholders to protect the value of their investment by voting for its nominee directors.
Ric Kayne, a significant shareholder of Athira Pharma (NASDAQ: ATHA), filed a proxy statement urging shareholders to replace CEO Dr. Mark Litton with more qualified leadership. Kayne argues that under current management, the chances of success for ATH-1017, a treatment for Alzheimer's, are jeopardized. He cites a 30% drop in market capitalization since Litton's appointment and questions the board's decision-making. The upcoming shareholders' meeting on May 19, 2022, presents an opportunity for change, with Kayne and former Novartis CFO George Bickerstaff as nominees.
Athira Pharma, Inc. (NASDAQ: ATHA) filed its definitive proxy statement with the SEC for the upcoming Annual Meeting on May 19, 2022, urging shareholders to vote for its director nominees on the WHITE proxy card. The company highlights effective execution against strategic priorities and anticipates topline results from the Phase 2 ACT-AD study by the end of Q2 2022. Athira is well-capitalized, positioned to meet clinical milestones, and emphasizes the expertise of its board nominees while opposing a disruptive proxy contest initiated by shareholder Richard A. Kayne.
Athira Pharma (NASDAQ: ATHA) announced the dosing of the first subject in a Phase 1 clinical trial for ATH-1020, aimed at treating neuropsychiatric conditions. This trial marks a crucial milestone as it is Athira's second clinical candidate and its first oral small molecule. The study will enroll approximately 68 healthy volunteers and will focus on the safety and tolerability of ATH-1020, which has shown promise in preclinical data by mitigating depression-like behaviors and normalizing sensory processing deficits in schizophrenia. Initial results are anticipated to guide future developments.